International application No.

PCT/SE 2004/001209

#### A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A01K 67/027
According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

### IPC7: A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

## SE, DK, FI, NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

# WPI, EPO-INTERNAL, PAJ, BIOSIS, EMBASE, MEDLINE

# C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 0176361 A1 (ELINUS AB), 18 October 2001 (18.10.2001), abstract, page 1, lines 5-14; page 4, lines 6-14; examples 1-6	1-9
	<del></del>	
Y	WO 02057783 A2 (GLAXO GROUP LIMITED), 25 July 2002 (25.07.2002), page 4, line 7 - line 16; page 6, line 15 - line 16; page 7, line 1 - line 13, page 8, line 9 - line 12; page 17, line 29 - page 18, line 12; page 20, line 4 - line 6; examples 2-4, claims 24 and 27-28	1-9
	<del></del>	
Y	Nature, Volume 422, March 13, 2003, Yasuaki Itoh et al, "Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40", page 6928, abstract	1-9
·		

Х	Further	documents	are listed in	the continuation	of Box C.
_ ^				mo commission	of Don C.

See patent family annex.

- Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- earlier application or patent but published on or after the international filing date "E"
- document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- document referring to an oral disclosure, use, exhibition or other
- document published prior to the international filing date but later than the priority date claimed
- later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search 17 January 2005

Date of mailing of the international search report 19 -01- 2005

Name and mailing address of the ISA/ Swedish Patent Office

Authorized officer

Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86

TERESE PERSSON/BS Telephone No. +46 8 782 25 00

International application No.
PCT/SE 2004/001209

C (Continu	ation). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Α	The Journal of Biological Chemistry, Volume 278, No. 13, March 2003, Celia P. Briscoe et al, "The Orphan G Protein-coupled Receptor GPR40 Is Activated by Medium and Long Chain Fatty Acids", pages 11303-11311	1-9
Ρ,Χ	DATABASE WPI Week 200363 Derwent Publication Ltd., London, GB; Class B04, AN 2003-671661 & W003068959 A1 (TAKEDA CHEM IND LTD),	1-9
	21 Augusti 2003 (2003-08-21) abstract	
	,	

International application No. PCT/SE2004/001209

Box No.	Nucleotide and/or amino acid sequence(s) (Continuation of item1.b of the first sheet)
1. With	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed
	ntion, the international search was carried out on the basis of:  pe of material
K-	<u> </u>
<u> </u>	
L	table(s) related to the sequence listing
h fo	ormat of material
· -	in written format
-	in computer readable form
2	
c. ti	me of filing/furnishing
	contained in the international application as filed
	filed together with the international application in computer readable form
[	furnished subsequently to this Authority for the purposes of search
2.	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Add	itional comments:

Information on patent family members

30/10/2004

International application No.

PCT/SE 2004/001209

						•		
W	כ	0176361	<b>A1</b>	18/10/2001	AT	247634	T	15/09/2003
					AU	4702201	Α	23/10/2001
		•			AU	6033400	Α	31/01/2001
					CA	2414652	Α .	18/10/2001
					DE	60004675	D,T	17/06/2004
		•			EP	1196376	A,B	17/04/2002
					SE	1196376	T3	
					EP	1292186	Α	19/03/2003
				•	IL	152135	D	00/00/0000
					JP	2003503382	T	28/01/2003
					JP	2003529379	T	07/10/2003
					SE	0001285	D	00/00/0000
					US	6770679	В	03/08/2004
					US	20030056240	Α	20/03/2003
					ZA	200208694	A	19/08/2003
				25 /07 /2002		1 25 4 200		22 /10 /2002
W	U	02057783	A2	25/07/2002	EP	1354200		22/10/2003
					GB	0031527		00/00/0000
					US	20040137517	A	15/07/2004

International application No. PCT/SE2004/001209

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

A diabetes type 2 model laboratory animal is disclosed which comprises cells over-expressing GPR 40 under the control of the Ipfl/Pdxl promoter. Also disclosed is the use of the model animal for the identification of agonists or antagonists towards GPR40, useful for the development of pharmaceuticals towards treatment of the disease.